Skip to main content

Express Scripts Value Stock - Dividend - Research Selection

Express Scripts

ISIN: US30219G1085, WKN: A1JWJL

Market price date: 30.11.-0001
Market price: 0,00 USD


Express Scripts Fundamental data and company key figures of the share

Annual reports in USD
Key figures 14-02-2018
Cash flow
Net operating cash flow 5.351.300.000
Capital Expenditures -267.400.000
Free cash flow 5.083.899.904
Balance sheet
Total Equity 18.119.600.000
Liabilities & Shareholders equity 54.255.800.000
Income statement
Net income 4.517.400.000
Eps (diluted) 7,740
Diluted shares outstanding 583.400.000
Net sales/revenue 100.065.000.000

Fundamental ratios calculated on: 30-11--0001

Ratios
Key figures 30-11--0001
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI0,00
ROE0,00
Income statement
P/E0,00
Div. Yield0,00%
P/B0,00
P/S0,00


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolESRX
Market Capitalization53.865.320.448,00 USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internetwww.express-scripts.com


Description of the company

Prescription drugs play a significant role in healthcare today and constitute the first line of treatment for many medical conditions. For many, prescription drugs provide the hope of improved health and quality of life.

Total medical costs for employers continue to outpace the rate of overall inflation, in particular, the increase in high cost drugs to treat complex conditions such as cancer, hepatitis and multiple sclerosis. National health expenditures as a percentage of gross domestic product are expected to increase to 19.6% in 2024 from an estimated 18.0% in 2015 according to the Centers for Medicare & Medicaid Services. With increasing cost pressures being exerted on health benefit providers such as managed care organizations, health insurers, employers and unions, there is an increasing role for pharmacy benefit management companies to develop innovative strategies to put medicine within reach of patients by making better health more affordable and accessible.

 

PBM companies typically combine retail pharmacy claims processing and network management, formulary management, utilization management and home delivery pharmacy services to develop an integrated product offering to manage the prescription drug benefit for payors. Some PBMs also offer specialty medication services that deliver a more effective solution than many retail pharmacies in providing treatments for diseases that rely upon high-cost injectable, infused, oral or inhaled drugs. Some PBMs have also broadened their service offerings to include medication adherence programs, outcomes research, drug therapy management programs, sophisticated data analysis and other distribution services.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.express-scripts.com


NEWS


Will fuboTV Inc. (FUBO) Be On Your List Of Penny Stocks In 2022?

2022-04-08